Comparative Pharmacology
Head-to-head clinical analysis: MACRILEN versus PORCINE SECRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACRILEN versus PORCINE SECRETIN.
MACRILEN vs PORCINE SECRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MACRILEN (macimorelin) is a synthetic growth hormone secretagogue receptor (GHS-R) agonist that stimulates growth hormone (GH) release from the anterior pituitary. It mimics the action of ghrelin, enhancing GH secretion through GHS-R activation.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
1 mg subcutaneously once daily, titrated as needed to a maximum of 2 mg daily.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2.5–4.5 hours) in healthy adults. This short half-life supports its use for diagnostic testing, with rapid clearance after stimulation of growth hormone release.
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
Primarily renal; approximately 90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized, with metabolites also eliminated renally. Fecal excretion is negligible (<2%).
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent